Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcus Biosciences (RCUS) Return on Sales (2017 - 2025)

Arcus Biosciences has reported Return on Sales over the past 9 years, most recently at 3.21% for Q4 2025.

  • Quarterly results put Return on Sales at 3.21% for Q4 2025, up 40.0% from a year ago — trailing twelve months through Dec 2025 was 1.43% (down 33.0% YoY), and the annual figure for FY2025 was 1.43%, down 33.0%.
  • Return on Sales for Q4 2025 was 3.21% at Arcus Biosciences, up from 5.19% in the prior quarter.
  • Over the last five years, Return on Sales for RCUS hit a ceiling of 0.79% in Q4 2021 and a floor of 8.24% in Q3 2021.
  • Median Return on Sales over the past 5 years was 2.89% (2023), compared with a mean of 3.43%.
  • Peak annual rise in Return on Sales hit 1773bps in 2021, while the deepest fall reached -827bps in 2021.
  • Arcus Biosciences' Return on Sales stood at 0.79% in 2021, then plummeted by -350bps to 1.97% in 2022, then crashed by -194bps to 5.79% in 2023, then surged by 38bps to 3.62% in 2024, then increased by 11bps to 3.21% in 2025.
  • The last three reported values for Return on Sales were 3.21% (Q4 2025), 5.19% (Q3 2025), and 1.14% (Q2 2025) per Business Quant data.